GM Expands Ignition Switch Recall, Apologizes to Consumers

General Motors (GM) is expanding an ignition switch recall announced last week, to include 1.6 million cars, and the auto maker has apologized to consumers for the problems that may have resulted in at least 13 deaths.  

On February 25, GM issued a press release announcing the ignition switch recall expansion.

The original recall was limited to certain 2005-2007 Chevrolet Cobalt and Pontiac G5 vehicles, as well as the Pontiac Pursuit, which was only sold in Canada. GM has now expanded the spoke of the recall to also include model year 2003-2007 Saturn Ions, 2006-2007 Chevrolet HHRs, and 2006-2007 Pontiac Solstice and Saturn Sky models.

Learn More About

GM Ignition Recall Lawsuits

In 2014, GM Recalled 2.6M Vehicles Due to Risk of Airbag Failure from Defective Ignition Switches.


The number of total vehicles affected now tops 1.6 million, with 1.3 million of those sold in the United States. The rest were sold in Canada and Mexico.

According to GM, the vehicles may turn themselves off during use due to a problem with the torque in the ignition switch. This can happen if heavy keys are used in the ignition or if the vehicle experiences an impact, like a rough road or a crash. If this happens, then the airbags may not deploy during a crash.

Adding in the expanded vehicle population, GM says it is aware of at least 31 incidents where the airbags failed to deploy during an auto accident that may have been due to this problem. The company said it is aware of at least 13 front-seat fatalities that were suffered in these accidents.

As part of the investigation into the incidents, GM submitted a detailed chronology of how it investigated the problem to the National Highway Traffic Safety Administration (NHTSA) on Monday. The report suggests that GM knew about the problem for years, but may have been slow to act. GM officials say that they are reviewing their investigation process.

“The chronology shows that the process employed to examine this phenomenon was not as robust as it should have been,” admitted GM North America President Alan Batey in the company’s press release. “Today’s GM is committed to doing business differently and better. We will take an unflinching look at what happened and apply lessons learned here to improve going forward.”

The company says it is going beyond the required written notifications for customers and is using customer records, social media and other communications channels to reach owners affected by the recall.

Once owners are notified, GM has instructed dealers to replace the ignition switches. In the meantime, those with affected vehicles should drive only using the ignition key, removing all unnecessary items from the key ring, the company advises.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted today)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 2 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.